|
Post by harryx1 on Jun 14, 2024 9:10:30 GMT -5
|
|
|
Post by Clement on Jun 18, 2024 9:20:17 GMT -5
UTHR is up over 300.00 this morning. What a nice run! I like the implications for MNKD.
|
|
|
Post by Clement on Jun 20, 2024 12:34:08 GMT -5
UTHR share price went over 311.00 today. Wow!
Some people new to the story might wonder what are the implications for MNKD. Tyvaso is by far the biggest growth driver for UTHR, and the MNKD- manufactured product Tyvaso-DPI is the major part of that. UTHR pays MNKD a royalty and manufacturing cost for UTHR revenues for T-DPI.
|
|
|
Post by peppy on Jun 24, 2024 7:22:48 GMT -5
Any chance MNKD share price continues up today, following UTHR? UTHR Monthly chart schrts.co/dYXNbzTb
|
|
|
Post by mytakeonit on Jun 24, 2024 12:53:05 GMT -5
Veeerrryyy likely ...
But, that's mytakeonit
|
|
|
Post by wyattdog on Jun 25, 2024 12:38:42 GMT -5
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension 10:22:50 AM ET, 06/25/2024 - MT Newswires 10:22 AM EDT, 06/25/2024 (MT Newswires) -- Tempus AI (TEM) said Tuesday it is launching a collaboration with United Therapeutics (UTHR) under which Tempus will develop artificial intelligence-backed medical device software to detect people at risk of having pulmonary hypertension.
Financial details of the collaboration weren't disclosed.
Tempus said it built an algorithm that analyzes the results of electrocardiograms to identify people at risk of the disease.
The algorithm will be deployed at participating medical centers, Tempus said, adding doctors will assess its ability to detect patients at risk.
Tempus and United Therapeutics will collaborate on the study to investigate the clinical impact of the technology, Tempus said.
Tempus also said it plans to engage with the US Food and Drug Administration to align on regulatory requirements and the FDA's expectations for validation of the algorithm.
Price: 23.69, Change: -1.62, Percent Change: -6.40
|
|
|
Post by Clement on Jun 25, 2024 13:27:08 GMT -5
^ Thanks, Wyatt!
Tempus and United Therapeutics. Why does this matter to MNKD stock. Wyatt knows but I'm going to try to explain.
UTHR has told us that there are a lot more people with PH-ILD than already diagnosed. Diagnosis requires a right heart cath, which is expensive. Tempus' algorithm for ID of PH through electrocardiograms (which are already done) would better ID those who would benefit from a right heart cath and perhaps PH-ILD diagnosis and therapy. Alternately, Temmpus' algorithm could bypass the RH cath requirement and directly qualify the patient for PH-ILD therapy. Sounds like a great win for patients and insurers!
It's eventually a win for MNKD because UTHR's Tyvaso-DPI for PH-ILD is a money-maker for MNKD.
|
|
|
Post by Clement on Jun 26, 2024 7:39:09 GMT -5
from Investors Business Daily: "Why United Therapeutics, An IBD 50 Stock, Has Surged 36% Over Nine Weeks" www.investors.com/research/the-new-america/united-therapeutics-biotech-stock-tyvaso-ipf-treatment/?src=A00220"Companies like Amgen (AMGN) or Bristol Myers Squibb (BMY) have old businesses that generate tons of cash. Then, there are smaller companies like BioMarin (BMRN) that work at the bleeding edge of research. As for United Therapeutics, it's a little bit of both, Steadman says. As of March 31, the company had $980 million in trailing 12 months cash flow. It's also planning to unveil the results of two key studies in 2025, which could help massively expand the potential market for its bread-and-butter drug, Tyvaso DPI."We're in a unique position among biotechs where we have a very strong, cash-generating commercial business with some defining clinical catalysts coming to head," Steadman told Investor's Business Daily in an interview. The biotech stock took off on its first-quarter report, delivered May 1. Since then, shares have rocketed more than 36% as of the close on June 24. United Therapeutics stock lands on the IBD 50 list of elite growth stocks."
|
|
|
Post by Clement on Jun 26, 2024 7:48:49 GMT -5
^ more
"The biotech stock climbed nearly 9% on May 1, following the quarterly report.
"We believe investors were encouraged by the revenue beat and by management voicing that they are starting to see a 'bend upwards' in Tyvaso's uptake trajectory that should continue in the quarters ahead as more revenue drivers kick in," Leerink Partners analyst Roanna Ruiz said in a note to clients at the time.
She has an outperform rating on the biotech stock.
Tyvaso Hits An Inflection Point United's Steadman acknowledges the first quarter represented something of an inflection point for United Therapeutics. Earlier this year, the company deployed an expanded sales force for Tyvaso in PH-ILD."
"
|
|
|
Post by cretin11 on Jun 26, 2024 10:54:09 GMT -5
Great prognosis for Tyvaso. I hope we don't sell off any more of our royalty.
|
|
|
Post by prcgorman2 on Jun 26, 2024 11:37:37 GMT -5
Great prognosis for Tyvaso. I hope we don't sell off any more of our royalty. To the contrary, it seems like the improved outlook means the extra $50M (IIRC) milestone-like kicker may activate making the 1% royalty sale an even better deal than it already is.
Frankly, I wouldn't care if they did sell off the remaining royalty if the deal was good enough. Banks sell their loans. MannKind could sell their remaining royalties. $1.45B to $1.8B in a non-debt cash infusion could be used to do a lot of interesting things. e.g., substantial stock buyback, expand or accelerate the pipeline, capacity builds, aggressive marketing of Afrezza (& eventually Clofazimine), increased compensation for executives , et cetera.
Mostly kidding. I prefer they do what they've set out to do with the cash from the 1% royalty sale and finish the job of retiring 100% of the remaining (toxic?) debt of $230M in convertible bonds, but I'm not closed-minded about options either if they're likely to provide a better return. "A dollar today is better than a dollar tomorrow" is the saying I heard oft repeated in corporate finance courses.
|
|
|
Post by cretin11 on Jun 26, 2024 14:51:40 GMT -5
Nah, don't sell off any more. Odds are good IMO that in any such negotiation, MC will probably not get the best end of it. That's only an opinion based on previous history, so you never know. But let's keep that 9%, another reason is the street might not trust our current team to use sales funds wisely, thus hurting our valuation. That's the counter to "a dollar today is better than a dollar tomorrow" plus of course the present value discount we know would apply. Again, JMO and it's a good topic to be able to discuss.
|
|
|
Post by prcgorman2 on Jun 26, 2024 15:16:49 GMT -5
MC has done a good job of rescuing MannKind from near bankruptcy, managing to keep the business going and progressing important goals even through COVID, eliminating debt and now successfully, if marginally, profitable with an outlook to be 100% debt free and potentially very profitable. I think your opinion that MC "will probably not get the best" deal is not the general consensus, at least of the Board of Directors. Indeed given that MNKD share price has increased ~500% since MC became CEO, I would say Wall Street doesn't share your opinion either.
|
|
|
Post by mytakeonit on Jun 26, 2024 15:19:40 GMT -5
And the August quarterly is coming up shortly ... and I assume it will show a continuation of ... outstanding growth.
|
|
|
Post by cretin11 on Jun 26, 2024 16:18:38 GMT -5
I’m sorry gorman but evidence is strong that Wall Street shares my view, but I know you will always want to believe otherwise. Of course that’s fine, as we can agree to disagree 👍🏼
|
|